vTv Therapeutics earnings release, August 6, 2026

vTv Therapeutics Inc. (VTVT) · Form 8-K, Item 2.02 · Filed · SEC filing

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D

HIGH POINT, N.C., August 6, 2026 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. The Company expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026. Based on its current cash position at the end of the second quarter of 2026, vTv expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout. In the fourth quarter of 2026, the Company also plans to host a Key Opinion Leader (KOL) event focused on T1D, the burden of managing hypoglycemia without compromising glycemic control, and cadisegliatin’s potential to address this significant unmet need.

“

Cadisegliatin has been specifically designed to address the significant unmet need of hypoglycemia, a major limiting factor in achieving optimal blood glucose control in T1D," said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. "We look forward to discussing cadisegliatin’s potential with leading experts in T1D at our planned fourth-quarter KOL event. With cash runway through our anticipated topline data readout, we are focused on advancing development of the potential first oral adjunctive therapy for people with T1D.”

Recent Company Highlights

• CATT1 Trial Advancing.

Enrollment in the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in individuals with T1D is expected to be completed in the third quarter of 2026.

• KOL Event on

Cadisegliatin

Program.

In the fourth quarter of 2026, the Company plans to host a KOL event focused on T1D, the significant unmet medical need of hypoglycemia, and the cadisegliatin

Phase 3 clinical program.

• Cadisegliatin

Hybrid Closed-Loop Trial (Hybrid CATT1). vTv expects to initiate the Phase 2a Hybrid CATT1 trial before year end 2026. This randomized, double-blind, crossover, multicenter study will evaluate cadisegliatin in T1D participants using hybrid closed-loop insulin delivery systems to inform the design and operational aspects of future Phase 3 research in this population.

Second Quarter 2026 Financial Results

• Cash Position

: Cash and cash equivalents as of June 30, 2026, were $86.6 million compared to $88.9 million as of December 31, 2025.

• Research & Development (R&D) Expenses

: R&D expenses were $8.8 million and $4.1 million for the three months ended June 30, 2026, and 2025, respectively. The increase was primarily driven by continued investment in the Phase 3 CATT1 trial.

• General & Administrative (G&A) Expenses:

G&A expenses were $5.2 million and $3.6 million for the three months ended June 30, 2026, and 2025, respectively. The increase reflects ongoing support for corporate operations and clinical development activities.

• Interest Income:

Interest income for the three months ended June 30, 2026, and 2025, of $0.8 million and $0.3 million, respectively, was related to dividend income from the Company's money market accounts.

• Net Loss

: Net loss attributable to vTv shareholders for the three months ended June 30, 2026, was $13.1 million or $1.05 per basic and diluted share. Net loss attributable to vTv shareholders for the comparable period a year ago was $6.0 million or $0.92 per basic and diluted share.

Upcoming Events

• H.C. Wainwright 28 th

Annual Global Investment Conference

Format: Fireside Presentation and 1x1 Investor Meetings

Location: New York, NY

Date: September 14-16, 2026

• 5th Annual ROTH Healthcare Opportunities Conference

Format: 1x1 Investor Meetings

Location: New York, NY

Date: September 29, 2026 vTv Therapeutics Inc.

Condensed Consolidated Balance Sheets

(in thousands) vTv Therapeutics Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

About vTv Therapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for T1D. In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether c adisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage.

Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin... (truncated) available for the use being investigat ed.

Financial statements

Income Statement

Three Months Ended June 30, — (in thousands, except per share data)

Three Months Ended June 30, – 2026 – (Unaudited)Three Months Ended June 30, – 2025 – (Unaudited)Six Months Ended June 30, – 2026 – (Unaudited)Six Months Ended June 30, – 2025 – (Unaudited)
Revenue$—36,839$—
Operating expenses:Research and development8,7704,10317,7486,933
Operating expenses:General and administrative5,1603,6189,7587,291
Operating expenses:Total operating expenses13,9307,72127,50614,224
Operating expenses:Operating (loss) income-13,930-7,7219,333-14,224
Operating expenses:Interest income8122751,650606
Operating expenses:Other income (expense), net64669721
Operating expenses:Net (loss) income before income taxes and noncontrolling interest-13,054-7,38011,080-13,597
Operating expenses:Net (loss) income before noncontrolling interest-13,054-7,38011,080-13,597
Operating expenses:Less: net loss attributable to noncontrolling interest-1,334-2,459
Operating expenses:Net (loss) income attributable to vTv Therapeutics Inc.-13,054-6,04611,080-11,138
Operating expenses:Net (loss) income attributable to vTv Therapeutics Inc. common shareholders-13,054-6,04611,080-11,138
Operating expenses:Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock-1.05-0.920.89-1.69
Operating expenses:Basic weighted average number of vTv Therapeutics Inc. Class A common stock12,409,3166,587,07012,409,2976,584,969
Operating expenses:Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock-1.05-0.920.76-1.69
Operating expenses:Diluted weighted average number of vTv Therapeutics Inc. Class A common stock12,409,3166,587,07014,541,7886,584,969

Balance Sheet

(in thousands)

June 30, 2026 – (Unaudited)December 31, 2025
Current assets:Cash and cash equivalents86,64388,932
Current assets:Prepaid expenses416743
Current assets:Other current assets530218
Current assets:Total current assets87,58989,893
Current assets:Other assets46
Current assets:Total assets87,59389,899
Current liabilities:Accounts payable and accrued expenses6,9926,557
Current liabilities:Warrant liability, related party2584
Current liabilities:Total current liabilities7,0176,641
Current liabilities:Contract liabilities1,83018,669
Current liabilities:Warrant liability114152
Current liabilities:Total liabilities8,96125,462
Stockholders’ equity:Class A Common Stock3939
Stockholders’ equity:Additional paid-in capital394,205391,090
Stockholders’ equity:Accumulated deficit-315,612-326,692
Stockholders’ equity:Total stockholders’ equity78,63264,437
Stockholders’ equity:Total liabilities and stockholders’ equity87,59389,899
Full release

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact

John Fraunces

LifeSci Advisors, LLC

917-355-2395 jfraunces@lifesciadvisors.com

Media Contact

Caren Begun

TellMed Strategies

201-396-8551 caren.begun@tmstrat.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · vTv Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.